ETON earnings analysis
What we found in ETON's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Eton delivered a strong Q2, with revenue of $37.568 million and diluted EPS of $0.43, materially above consensus and sharply improved versus both the prior quarter and prior-year period. Operating margin reached 34.0% and adjusted EBITDA margin was 43%, while management raised full-year revenue and EBITDA margin expectations. The principal offset is $27.0 million of variable-rate debt, alongside up to $7 million of identified ASN-001 and ALKINDI-related costs.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue growth and major consensus beat
- Q2 revenue was $37.568 million, up approximately 56% from $24 million in Q1 2026 and approximately 98% from $19 million in Q2 2025. Revenue exceeded the $27.139 million consensus estimate by approximately 38%.
- EPS turned strongly positive
- Diluted EPS was $0.43 versus $0.05 in Q1 2026 and a $(0.10) loss in Q2 2025. EPS exceeded the $0.18 consensus estimate by $0.25.
- Operating profitability expanded
- GAAP operating margin expanded to 34.0%, compared with 9.9% in Q1 2026 and negative 7.8% in Q2 2025, indicating substantial operating leverage.
- EBITDA margin exceeded raised target
- Adjusted EBITDA margin reached 43%, above the company’s increased full-year 2026 target of at least 35%.
- Full-year outlook raised
- The company raised 2026 revenue expectations to more than $145 million from more than $120 million and raised adjusted EBITDA margin expectations to at least 35% from at least 30%.
- No reported control deficiencies
- Disclosure controls were concluded effective as of June 30, 2026, and the company reported no changes in internal controls that materially affected or were reasonably likely to materially affect financial reporting.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Variable-rate debt and interest exposure
- The company had $27.0 million of borrowings outstanding under its variable-rate credit agreement as of June 30, 2026, with interest indexed to SOFR plus 6.55%, creating exposure to higher interest expense.
- Pipeline and milestone cash costs
- The 2026 outlook includes a $3 million ASN-001 licensing expense and a potential $4 million ALKINDI SPRINKLE milestone payment, which could pressure near-term earnings and cash flow if incurred.
- Warrant-related dilution without proceeds
- The company issued 296,215 common shares through cashless warrant exercises during the quarter; 62,901 warrants were surrendered and the company received no cash proceeds, creating dilution without a financing inflow.
- No new formal risk-factor additions
- The filing states that no new risk factors were identified relative to the 2025 10-K; however, the company remains exposed to institutional concentration and investment risks, including cash deposits and a government money market fund as of June 30, 2026.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $0.43
- Operating margin
- 34.0%
What they said about what is next.
Management raised 2026 revenue outlook to more than $145 million from more than $120 million and increased adjusted EBITDA margin guidance to at least 35% from at least 30%. The outlook includes a $3 million ASN-001 licensing expense and a potential $4 million ALKINDI SPRINKLE milestone payment.
The filing reads better than the one before it.
What came before.
- 10-Q · May 14, 2026
- Eton Pharmaceuticals delivered a strong performance in Q1 2026 with total revenues increasing to $24.27 million, up from $17.28 million year-over-year. The company's diluted EPS improved to $0.14 compared to a loss of…
- 10-K · March 19, 2026
- Eton positions itself as a rare-disease specialty pharma with an acquisitive, BD-led strategy: 8 commercial products and five late-stage candidates (including ET-600 with a PDUFA date of February 25, 2026). Recent…
- 10-Q · November 6, 2025
- Eton reported Q3 2025 revenue of $22,459,000 (vs. $10,324,000 in Q3 2024) and gross profit of $7,855,000, but recorded a GAAP net loss of $1,927,000 (GAAP EPS $(0.07) basic). Operating results reflect higher R&D and G&A…
- 10-Q · May 13, 2025
- Eton Pharmaceuticals reported Q1 2025 results showing a significant increase in total revenues to $17.28 million, up from $7.97 million in Q1 2024. The gross margin decreased slightly to 57.1% from 62.9% in the prior…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing ETON makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever